Janux Therapeutics Statistics
Share Statistics
Janux Therapeutics has 57.80M shares outstanding. The number of shares has increased by 11.88% in one year.
| Shares Outstanding | 57.80M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 10.8% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 46.79M |
| Failed to Deliver (FTD) Shares | 1.58K |
| FTD / Avg. Volume | 0.14% |
Short Selling Information
The latest short interest is 6.41M, so 11.1% of the outstanding shares have been sold short.
| Short Interest | 6.41M |
| Short % of Shares Out | 11.1% |
| Short % of Float | 13.65% |
| Short Ratio (days to cover) | 4.32 |
Valuation Ratios
The PE ratio is -8.1 and the forward PE ratio is -33.02.
| PE Ratio | -8.1 |
| Forward PE | -33.02 |
| PS Ratio | 58.43 |
| Forward PS | 204.1 |
| PB Ratio | 1.37 |
| P/FCF Ratio | -9.01 |
| PEG Ratio | n/a |
Enterprise Valuation
Janux Therapeutics Inc. has an Enterprise Value (EV) of 477.63M.
| EV / Earnings | -8.19 |
| EV / Sales | 59.09 |
| EV / EBITDA | -6.72 |
| EV / EBIT | -6.54 |
| EV / FCF | -9.11 |
Financial Position
The company has a current ratio of 26.8, with a Debt / Equity ratio of 0.
| Current Ratio | 26.8 |
| Quick Ratio | 26.8 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.17% and return on capital (ROIC) is -19.78%.
| Return on Equity (ROE) | -0.17% |
| Return on Assets (ROA) | -0.15% |
| Return on Capital (ROIC) | -19.78% |
| Revenue Per Employee | 106.36K |
| Profits Per Employee | -767.01K |
| Employee Count | 76 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 367.8% in the last 52 weeks. The beta is 3.52, so Janux Therapeutics 's price volatility has been higher than the market average.
| Beta | 3.52 |
| 52-Week Price Change | 367.8% |
| 50-Day Moving Average | 54.1 |
| 200-Day Moving Average | 47.86 |
| Relative Strength Index (RSI) | 35 |
| Average Volume (20 Days) | 1.09M |
Income Statement
In the last 12 months, Janux Therapeutics had revenue of 8.08M and earned -58.29M in profits. Earnings per share was -1.32.
| Revenue | 8.08M |
| Gross Profit | 6.13M |
| Operating Income | -72.98M |
| Net Income | -58.29M |
| EBITDA | -71.02M |
| EBIT | -72.98M |
| Earnings Per Share (EPS) | -1.32 |
Balance Sheet
The company has 19.20M in cash and 24.54M in debt, giving a net cash position of -5.34M.
| Cash & Cash Equivalents | 19.20M |
| Total Debt | 24.54M |
| Net Cash | -5.34M |
| Retained Earnings | -168.76M |
| Total Assets | 695.02M |
| Working Capital | 649.15M |
Cash Flow
In the last 12 months, operating cash flow was -50.58M and capital expenditures -1.85M, giving a free cash flow of -52.42M.
| Operating Cash Flow | -50.58M |
| Capital Expenditures | -1.85M |
| Free Cash Flow | -52.42M |
| FCF Per Share | -1.19 |
Margins
Gross margin is 75.81%, with operating and profit margins of -902.87% and -721.18%.
| Gross Margin | 75.81% |
| Operating Margin | -902.87% |
| Pretax Margin | -721.18% |
| Profit Margin | -721.18% |
| EBITDA Margin | -878.68% |
| EBIT Margin | -902.87% |
| FCF Margin | -648.58% |
Dividends & Yields
JANX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2.91% |
| FCF Yield | -2% |
Analyst Forecast
The average price target for JANX is $70, which is 54.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $70 |
| Price Target Difference | 54.4% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | 47.6 |
| Piotroski F-Score | 3 |